Wuxi Hyatech Co

Wuxi Hyatech Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Wuxi Hyatech Co (688510.SS) as of Oct 22, 2026 is 25.07 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 11.27 % — a change of 122.37% (higher).

FCF Conversion

25.07 %

YoY

122.37%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Wuxi Hyatech Co is 2025 25.07 % . FCF Conversion Rate (FCF/EBITDA) of Wuxi Hyatech Co was 2024 11.27 % . It decreases by 122.37% higher compared to the previous year.

The Wuxi Hyatech Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-530.55 CNY
Jan 1, 2019
-144.05 CNY
Jan 1, 2020
-80.06 CNY
Jan 1, 2021
-293.25 CNY
Jan 1, 2022
-890.26 CNY
Jan 1, 2023
-108.15 CNY
Jan 1, 2024
11.27 CNY
Jan 1, 2025
25.07 CNY
The Wuxi Hyatech Co FCF Conversion history
YEARFCF ConversionYoY
25.07 %+122.37%
11.27 %-110.42%
-108.15 %-87.85%
-890.26 %+203.58%
-293.25 %+266.30%
-80.06 %-44.42%
-144.05 %-72.85%
-530.55 %-236.12%
389.78 %-0.51%
391.79 %+13.51%
345.16 %+38.17%
249.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Wuxi Hyatech Co Stock analysis

What does Wuxi Hyatech Co do? Wuxi Hyatech Co Ltd generates revenue through the research and development, manufacturing, and sales of key components for aero-engines and medical orthopedic implant forgings. The company produces high-performance components including aviation turbofan engine compressor blades, rotating parts, and structural parts, which are sold domestically and internationally. Its primary customers are aerospace manufacturers and medical device companies requiring specialized forgings for engine parts and orthopedic implants. The firm targets the aerospace and medical sectors with its focus on precision-engineered components for critical applications. The company's product portfolio includes aviation turbofan engine compressor blades, rotating parts, and structural parts, alongside medical orthopedic implant forgings. These products are distributed across domestic and overseas markets, serving both the Chinese aerospace industry and international medical device markets. Wuxi Hyatech's revenue streams are derived from direct sales of these specialized components to industrial and medical clients without third-party intermediaries. Wuxi Hyatech's business model centers on supplying high-precision components for aero-engines and medical orthopedic implants. The company's manufacturing capabilities enable it to produce critical parts for aircraft engines and orthopedic devices, with a focus on domestic and international industrial clients. Revenue is generated through the sale of these specialized forgings to aerospace and medical sectors, leveraging its R&D expertise in component production. Wuxi Hyatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Wuxi Hyatech Co stock

FCF Conversion Rate (FCF/EBITDA) of Wuxi Hyatech Co is 25.07 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Wuxi Hyatech Co changed from 11.27 % to 25.07 %, representing a 122.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Wuxi Hyatech Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Wuxi Hyatech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Wuxi Hyatech Co

All Key Metrics — Wuxi Hyatech Co